The Effect of Insulin on Infarct Size and Neurologic Outcome After Acute Stroke

Completed

Phase N/A Results N/A

Trial Description

Between twenty and fifty percent of people who have acute stroke have hyperglycemia (high blood sugar) with it. Research has shown an association between hyperglycemia and poor recovery from stroke. However, it is not known if treating the hyperglycemia—bringing the blood sugar back to normal range—will improve the patient's recovery from stroke. This purpose of this study is to see if giving Insulin to normalize the blood sugar will decrease the size of the stroke in the brain and improve the patient's neurologic recovery.
We hypothesize that early insulin administration to normalize blood glucose levels may be beneficial in cerebral ischemia and stroke.

Detailed Description

Insulin, by lowering blood glucose levels, has been shown to rescue ischemically threatened but potentially viable tissue of the penumbra surrounding the core of dead tissue. Insulin appears to act directly on the neuron and indirectly by lowering peripheral blood glucose. It has proven effective in animal models of stroke, and has a favorable toxicologic and cardiovascular profile. Dosing in this study will be individualized. The initial dose and subsequent doses will be modulated to maintain serum glucose levels between 80 and 110 mg/dL.
The first objective of this study is to determine the safety and efficacy of intravenous insulin versus Standard Treatment in patients with suspected cerebral infarction. The primary outcome parameter will be infarct volume at Week 1 as measured on diffusion - perfusion magnetic resonance imaging. Secondary analyses of efficacy will be the effect of insulin on neurologic function as measured by the Modified Rankin Scale, the National Institutes of Health Stroke Scale, and the Barthel Index. Analysis of safety will include analyses of physical exam, adverse events, vital signs, laboratory data, hemorrhage and reinfarction rates and mortality rates.

Conditions

Interventions

  • Insulin Drug
    ARM 1: Kind: Experimental
    Label: Insulin

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Outcomes

Type Measure Time Frame Safety Issue
Primary Change in infarct volume at Week 1 from baseline as measured on diffusion - perfusion magnetic resonance imaging baseline to one week No
Primary Analyses of group mean infarct volume and the mean percent change from baseline to Week 1 baseline to one week No
Secondary Blood sugar hour 0.25, 0.5, 1, 2,4,6,8,12,16,20,24, 36, 48 Yes
Secondary Coagulation Studies hour 0, 6,12,24,48 No
Secondary Neurological Assessment: NIHSS, Barthel Index, Modified Rankin Score hr 0, 48, week 1 and week 12 No
Secondary Mortality rates hour 0 to one week Yes

Sponsors